Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7359122 | 0.74 | CRBN (0.64) | NPSR1KDM4EGAAPOLBGRIN1 | |
| SCHEMBL8338197 | 0.73 | KMT2A (0.32) | KMT2ACRBNBRD4BRD2 | |
| Ethane SCHEMBL301523 | 0.73 | — | — | |
| N-Methylpiperidine SCHEMBL3452502 | 0.73 | — | — | |
| N-Methylpiperidine SCHEMBL9042506 | 0.73 | TDP1 (0.36) | KDM4ELMNA | |
| SCHEMBL12316976 | 0.72 | HRH3 (0.37) | KDM4ELMNAALDH1A1 | |
| N-Methylpiperidine SCHEMBL1920 | 0.72 | — | — | |
| SCHEMBL414741 | 0.72 | HRH3 (0.37) | KDM4ELMNAALDH1A1 | |
| SCHEMBL12952612 | 0.72 | HRH3 (0.37) | KDM4ELMNAALDH1A1 | |
| SCHEMBL21960469 | 0.72 | HRH3 (0.37) | KDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| EP-4397309-A2 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| CN-111278809-B | Bicyclic sulfones and sulfoxides, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240190886-A1 | BRM Targeting Compounds and Associated Methods of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-06-13 | — | — | US | disclosed |
| WO-2024107711-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-20240076295-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2024-03-07 | — | — | US | disclosed |
| EP-4313986-A1 | PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDS | Genentech, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240034739-A1 | PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDS | GENENTECH, INC. (US) | 2024-02-01 | — | — | US | disclosed |
| EP-3652178-B1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-2968280-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970156-A2 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105263490-A | Substituted triazolopyridines and methods of use | GENENTECH INC | 2016-01-20 | — | — | CN | disclosed |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2016-01-14 | — | — | US | disclosed |
| WO-2016007534-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20160009667-A1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2014153037-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014144545-A2 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190886-A1 | BRM Targeting Compounds and Associated Methods of Use | ADRM1, BRDT, RBX1 | NPSR1 4135/4885KDM4E 2075/4885GAA 2773/4885 |
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | CACNA1E, TRPV1, SCN3A | NPSR1 180/4885KDM4E 2052/4885GAA 4690/4885 |
| US-20240076295-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | NPSR1 4298/4885KDM4E 2143/4885GAA 1497/4885 |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | P2RX3, P2RX1, P2RX4 | NPSR1 261/4885KDM4E 4288/4885GAA 3264/4885 |
| US-20240034739-A1 | PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDS | HSD17B7, BCKDK, CYP11B1 | NPSR1 1400/4885KDM4E 1279/4885GAA 2517/4885 |
| US-20160009667-A1 | SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF | CYP4X1, BRIX1, HAX1 | NPSR1 288/4885KDM4E 2612/4885GAA 2222/4885 |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | NPSR1 1528/4885KDM4E 1362/4885GAA 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.